- Home
- COAG vs NSSC Comparison
COAG vs NSSC Comparison
Compare COAG & NSSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COAG | NSSC |
|---|---|---|
| Founded | N/A | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2026 | 1994 |
Fundamental Metrics
Financial Performance| Metric | COAG | NSSC |
|---|---|---|
| Price | $29.83 | $39.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.17 |
| AVG Volume (30 Days) | 252.9K | ★ 484.8K |
| Earning Date | N/A | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | N/A | ★ $181,621,000.00 |
| Revenue This Year | N/A | $13.63 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | ★ N/A | $53.99 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.47 | $29.27 |
| 52 Week High | $38.87 | $47.61 |
Technical Indicators
Market Signals| Indicator | COAG | NSSC |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 61.85 |
| Support Level | $27.47 | $37.43 |
| Resistance Level | $38.87 | $44.46 |
| Average True Range (ATR) | 3.77 | 1.17 |
| MACD | 0.02 | 0.32 |
| Stochastic Oscillator | 22.98 | 96.56 |
Price Performance
Historical ComparisonAbout COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.